The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

University Hospital, Gentofte, Copenhagen

Status: Completed

Conditions: Diabetes Mellitus

Treatments: Other: GLP-2 infusion; Other: Sodium-chloride; Other: GIP-infusion

Study type: Interventional

Funder types: Other

Identifiers

NCT00732602

H-D-2007-0058

Details and patient eligibility

About

The purpose of this study is to determine whether Glucose-dependent Insulinotropic Polypeptide (GIP) or Glucagon Like Peptide 2 (GLP-2) has an affect on the secretion of Glucagon from the pancreas in patients with type 1 diabetes mellitus.

Enrollment: 8 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Caucasians over 18 years with type 1 diabetes (WHO criteria)
• Arginine test without rise in plasma C-peptide
• Normal blood Hemoglobin
• Informed consent

Exclusion criteria

• Liver disease
• Diabetic nephropathy
• Treatment with medications unpausable for 12 hours

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

8 participants in 3 patient groups, including a placebo group

B

Active Comparator group

Description:

GLP-2 infusion

Treatment:

Other: GLP-2 infusion

C

Placebo Comparator group

Description:

Sodium-chloride infusion

Treatment:

Other: Sodium-chloride

A

Active Comparator group

Description:

GIP-infusion

Treatment:

Other: GIP-infusion